-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Growth differentiation factors 15 (GDF15) and N end of the type B sodium peptide prebiogen (NT-proBNP) are expected to be biomarkers of cognitive outcomes, including dementia.
, researchers identified a link between these biomarkers and cognitive outcomes in a community-based queue, according to a recent study published in JAHA, an authoritative journal in the field of cardiovascular disease.
researchers measured plasma GDF15 (n-1603) and NT-proBNP (n-1590) levels of participants in the dementia-free Fleming hanzi queue (53 percent of women; an average age of 68.7 years), and followed participants with dementia events.
the study included Alzheimer's disease dementia, magnetic resonance imaging of structural brain indicators, and neurocognitive function.
131 participants developed dementia during an average of 11.8 years of follow-up.
In the multivariate Cox proportional risk analysis, higher cyclical GDF15 was associated with an increased risk of developing all-cause and Alzheimer's disease (biomarker value natural pair conversion was 1.54 (95% CI 1.22-1.1.) per elevated SD. 95) and 1.37 (95% CI is 1.03-1.81) and elevated plasma NT-proBNP is also associated with an increased risk of all-cause dementia (HR is 1.32; 95% CI is 1.05-1.65).
GDF15 was associated with lower total brain and sea mass, higher whiteness, high blood volume, and poor cognitive performance.
increase in NT-proBNP was associated with increased whiteness and poor cognitive ability.
addition of two biomarkers to the general risk factor model can improve the classification of dementia risk (net reclassification improvement index is 0.25; 95% CI is 0.05-0.45).
result, elevated plasma GDF15 and NT-proBNP were associated with an increased risk of MRI vascular brain damage, poor neurocognitive function, and dementia in participants over 60 years of age.
both biomarkers improved the classification of dementia risk and went beyond traditional clinical risk factors, indicating their potential value in predicting dementia.
.
